Prosensa It uses a unique and revolutionary licensed technology platform that makes use of so-called exon skipping for correcting mutated RNA. The company primarily targets the Duchenne Muscular Dystrophy (DMD) disorder, against which it has already developed two products that are currently in clinical phase I / II.
Prosensa was acquired by BioMarin Pharmaceutical on November 27, 2014.
Join Mergr to view all 361 acquisitions of healthcare services companies in 2014, including 48 acquisitions by private equity firms, and 313 by strategics.
Out of 60 sectors in the Mergr database, healthcare services ranked 5 in number of deals in 2014. The largest healthcare services acquisition in 2014 was CareFusion - which was acquired by Becton Dickinson for $12.2B.
Join Mergr to view this profile - and discover more healthcare services acquisitions of companies like Prosensa.
No obligation. Cancel anytime.